M.D. Anderson Cancer Center
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
PRIMARY OBJECTIVE: The primary objective is to estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer SECONDARY OBJECTIVES: * To estimate overall survival (OS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer * To evaluate toxicity and morbidity of secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer * To estimate quality of life after secondary cytoreductive surgery and HIPEC for women with recurrent…
Inclusion Criteria: * Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer * Age ≥18 years * ECOG performance status ≤ 2 * Prior to surgery, patients must have adequate organ and marrow function as defined below (within 30 days of registration): 1. absolute neutrophil count \>1,500/mcL 2. platelets \>100,000/mcL 3. total bilirubin ≤ 1.5 mg/dL 4. creatinine ≤ 1.5 mg/dL 5. AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal * Patients must be \> 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab tre…
(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
Arctuva estimate
Verify or correct the compensation shown for this listing.